Isofol Medical (ISOFOL) Q2 2024 earnings summary

Executive summary

• New preclinical studies confirm a dose-response relationship for arfolitixorin, supporting the clinical development plan.

• A collaboration agreement was signed with Charité - Universitätsmedizin Berlin for the next clinical phase.

• Post hoc analysis of the AGENT phase III study suggests improved outcomes for arfolitixorin with better protocol adherence.

• Recruitment for a new phase Ib/II clinical study is planned before year-end 2024/2025.

• Margareta Hagman appointed as CFO, effective August 13, 2024.

Financial highlights

• Net sales were 0 TSEK for Q2 2024 (0 TSEK in Q2 2023) and 0 TSEK for H1 2024 (721 TSEK in H1 2023).

• Q2 2024 net loss was -11,045 TSEK (Q2 2023: -7,552 TSEK); H1 2024 net loss was -19,527 TSEK (H1 2023: -21,942 TSEK).

• Cash and bank at June 30, 2024: 119,150 TSEK (June 30, 2023: 156,717 TSEK).

• No loans outstanding as of June 30, 2024.

• Operating cash flow for H1 2024 was -19,001 TSEK (H1 2023: -33,833 TSEK).

Outlook and guidance

• The company is preparing to initiate a phase Ib/II clinical trial of arfolitixorin in metastatic colorectal cancer before year-end 2024/2025.

• Optimism is based on new preclinical and post hoc clinical data supporting higher dosing.

• No guarantee of clinical success; outcomes may vary due to economic, regulatory, or market changes.